<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2 xmlns:ns2="local" rowCount="110"><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="2659">Cardioprotectant</Action><Company id="1010999">Takara Bio Europe Ab</Company><Country id="DK">Denmark</Country><Drug></Drug><ParentCompany id="30651">Takara Holdings Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA2917454">WO-2004099394</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="2659">Cardioprotectant</Action><Company id="1010999">Takara Bio Europe Ab</Company><Country id="US">US</Country><Drug></Drug><ParentCompany id="30651">Takara Holdings Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA2917454">WO-2004099394</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="2659">Cardioprotectant</Action><Company id="1010999">Takara Bio Europe Ab</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="30651">Takara Holdings Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA2917454">WO-2004099394</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>3</StatusSortCode><Action id="7214">Genetic diagnostic agent</Action><Company id="16994">Hospital for Sick Children</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Status id="GRT">Granted</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="7214">Genetic diagnostic agent</Action><Company id="16994">Hospital for Sick Children</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="7214">Genetic diagnostic agent</Action><Company id="16994">Hospital for Sick Children</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>3</StatusSortCode><Action id="7211">CNS diagnostic agent</Action><Company id="16994">Hospital for Sick Children</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Status id="GRT">Granted</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="7211">CNS diagnostic agent</Action><Company id="16994">Hospital for Sick Children</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="7211">CNS diagnostic agent</Action><Company id="16994">Hospital for Sick Children</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>3</StatusSortCode><Action id="7162">Glucosylceramidase inhibitor</Action><Company id="16994">Hospital for Sick Children</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Status id="GRT">Granted</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="7162">Glucosylceramidase inhibitor</Action><Company id="16994">Hospital for Sick Children</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="7162">Glucosylceramidase inhibitor</Action><Company id="16994">Hospital for Sick Children</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>3</StatusSortCode><Action id="676">Beta-N-acetylhexosaminidase inhibitor</Action><Company id="16994">Hospital for Sick Children</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Status id="GRT">Granted</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="676">Beta-N-acetylhexosaminidase inhibitor</Action><Company id="16994">Hospital for Sick Children</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="676">Beta-N-acetylhexosaminidase inhibitor</Action><Company id="16994">Hospital for Sick Children</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>3</StatusSortCode><Action id="184">Alpha-glucosidase inhibitor</Action><Company id="16994">Hospital for Sick Children</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Status id="GRT">Granted</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="184">Alpha-glucosidase inhibitor</Action><Company id="16994">Hospital for Sick Children</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="184">Alpha-glucosidase inhibitor</Action><Company id="16994">Hospital for Sick Children</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>3</StatusSortCode><Action id="7214">Genetic diagnostic agent</Action><Company id="20525">University of Alberta</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="20525">University of Alberta</ParentCompany><Status id="GRT">Granted</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="7214">Genetic diagnostic agent</Action><Company id="20525">University of Alberta</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="20525">University of Alberta</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="7214">Genetic diagnostic agent</Action><Company id="20525">University of Alberta</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="20525">University of Alberta</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>3</StatusSortCode><Action id="7211">CNS diagnostic agent</Action><Company id="20525">University of Alberta</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="20525">University of Alberta</ParentCompany><Status id="GRT">Granted</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="7211">CNS diagnostic agent</Action><Company id="20525">University of Alberta</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="20525">University of Alberta</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="7211">CNS diagnostic agent</Action><Company id="20525">University of Alberta</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="20525">University of Alberta</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>3</StatusSortCode><Action id="7162">Glucosylceramidase inhibitor</Action><Company id="20525">University of Alberta</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="20525">University of Alberta</ParentCompany><Status id="GRT">Granted</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="7162">Glucosylceramidase inhibitor</Action><Company id="20525">University of Alberta</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="20525">University of Alberta</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="7162">Glucosylceramidase inhibitor</Action><Company id="20525">University of Alberta</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="20525">University of Alberta</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>3</StatusSortCode><Action id="676">Beta-N-acetylhexosaminidase inhibitor</Action><Company id="20525">University of Alberta</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="20525">University of Alberta</ParentCompany><Status id="GRT">Granted</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="676">Beta-N-acetylhexosaminidase inhibitor</Action><Company id="20525">University of Alberta</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="20525">University of Alberta</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="676">Beta-N-acetylhexosaminidase inhibitor</Action><Company id="20525">University of Alberta</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="20525">University of Alberta</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>3</StatusSortCode><Action id="184">Alpha-glucosidase inhibitor</Action><Company id="20525">University of Alberta</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="20525">University of Alberta</ParentCompany><Status id="GRT">Granted</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="184">Alpha-glucosidase inhibitor</Action><Company id="20525">University of Alberta</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="20525">University of Alberta</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="184">Alpha-glucosidase inhibitor</Action><Company id="20525">University of Alberta</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="20525">University of Alberta</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>3</StatusSortCode><Action id="7214">Genetic diagnostic agent</Action><Company id="21238">McMaster University</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="21238">McMaster University</ParentCompany><Status id="GRT">Granted</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="7214">Genetic diagnostic agent</Action><Company id="21238">McMaster University</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="21238">McMaster University</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="7214">Genetic diagnostic agent</Action><Company id="21238">McMaster University</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="21238">McMaster University</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>3</StatusSortCode><Action id="7211">CNS diagnostic agent</Action><Company id="21238">McMaster University</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="21238">McMaster University</ParentCompany><Status id="GRT">Granted</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="7211">CNS diagnostic agent</Action><Company id="21238">McMaster University</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="21238">McMaster University</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="7211">CNS diagnostic agent</Action><Company id="21238">McMaster University</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="21238">McMaster University</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>3</StatusSortCode><Action id="7162">Glucosylceramidase inhibitor</Action><Company id="21238">McMaster University</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="21238">McMaster University</ParentCompany><Status id="GRT">Granted</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="7162">Glucosylceramidase inhibitor</Action><Company id="21238">McMaster University</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="21238">McMaster University</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="7162">Glucosylceramidase inhibitor</Action><Company id="21238">McMaster University</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="21238">McMaster University</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>3</StatusSortCode><Action id="676">Beta-N-acetylhexosaminidase inhibitor</Action><Company id="21238">McMaster University</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="21238">McMaster University</ParentCompany><Status id="GRT">Granted</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="676">Beta-N-acetylhexosaminidase inhibitor</Action><Company id="21238">McMaster University</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="21238">McMaster University</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="676">Beta-N-acetylhexosaminidase inhibitor</Action><Company id="21238">McMaster University</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="21238">McMaster University</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>3</StatusSortCode><Action id="184">Alpha-glucosidase inhibitor</Action><Company id="21238">McMaster University</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="21238">McMaster University</ParentCompany><Status id="GRT">Granted</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="184">Alpha-glucosidase inhibitor</Action><Company id="21238">McMaster University</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="21238">McMaster University</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="184">Alpha-glucosidase inhibitor</Action><Company id="21238">McMaster University</Company><Country id="US">US</Country><Drug id="13513">probucol</Drug><ParentCompany id="21238">McMaster University</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>General interest</DrugRelationship><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Patent id="PA3074149">US-07488721</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="1767">Protein synthesis modulator</Action><Company id="1016838">FoldRx Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug></Drug><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3531567">WO-2007089548</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="1767">Protein synthesis modulator</Action><Company id="1016838">FoldRx Pharmaceuticals Inc</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3531567">WO-2007089548</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="10443">Rab GTPase modulator</Action><Company id="1016838">FoldRx Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug></Drug><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3531567">WO-2007089548</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="10443">Rab GTPase modulator</Action><Company id="1016838">FoldRx Pharmaceuticals Inc</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3531567">WO-2007089548</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="7162">Glucosylceramidase inhibitor</Action><Company id="16994">Hospital for Sick Children</Company><Country id="US">US</Country><Drug></Drug><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA4628162">WO-2009049421</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="7162">Glucosylceramidase inhibitor</Action><Company id="16994">Hospital for Sick Children</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA4628162">WO-2009049421</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="9223">Sulfatase stimulator</Action><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="WO">World</Country><Drug id="38270">elosulfase alfa</Drug><ParentCompany id="25861">BioMarin Pharmaceutical Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5324622">WO-2009091994</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="9223">Sulfatase stimulator</Action><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="US">US</Country><Drug id="38270">elosulfase alfa</Drug><ParentCompany id="25861">BioMarin Pharmaceutical Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA5324622">WO-2009091994</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="7214">Genetic diagnostic agent</Action><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="WO">World</Country><Drug id="38270">elosulfase alfa</Drug><ParentCompany id="25861">BioMarin Pharmaceutical Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5324622">WO-2009091994</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="7214">Genetic diagnostic agent</Action><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="US">US</Country><Drug id="38270">elosulfase alfa</Drug><ParentCompany id="25861">BioMarin Pharmaceutical Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA5324622">WO-2009091994</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="60172">N-acetylgalactosamine 6 sulfatase stimulator</Action><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="WO">World</Country><Drug id="38270">elosulfase alfa</Drug><ParentCompany id="25861">BioMarin Pharmaceutical Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5324622">WO-2009091994</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="60172">N-acetylgalactosamine 6 sulfatase stimulator</Action><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="US">US</Country><Drug id="38270">elosulfase alfa</Drug><ParentCompany id="25861">BioMarin Pharmaceutical Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA5324622">WO-2009091994</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="18440">Alpha-L-iduronidase modulator</Action><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="WO">World</Country><Drug id="38270">elosulfase alfa</Drug><ParentCompany id="25861">BioMarin Pharmaceutical Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5324622">WO-2009091994</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="18440">Alpha-L-iduronidase modulator</Action><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="US">US</Country><Drug id="38270">elosulfase alfa</Drug><ParentCompany id="25861">BioMarin Pharmaceutical Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA5324622">WO-2009091994</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="9201">Beta-glycosidase stimulator</Action><Company id="1053857">International University Of Health &amp; Welfare</Company><Country id="ES">Spain</Country><Drug></Drug><ParentCompany id="1053857">International University Of Health &amp; Welfare</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA5579673">WO-2010046517</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="9201">Beta-glycosidase stimulator</Action><Company id="1053857">International University Of Health &amp; Welfare</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="1053857">International University Of Health &amp; Welfare</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5579673">WO-2010046517</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="7149">Beta-galactosidase inhibitor</Action><Company id="1053857">International University Of Health &amp; Welfare</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="1053857">International University Of Health &amp; Welfare</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5579673">WO-2010046517</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="186">Beta-glucosidase inhibitor</Action><Company id="1053857">International University Of Health &amp; Welfare</Company><Country id="ES">Spain</Country><Drug></Drug><ParentCompany id="1053857">International University Of Health &amp; Welfare</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA5579673">WO-2010046517</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="186">Beta-glucosidase inhibitor</Action><Company id="1053857">International University Of Health &amp; Welfare</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="1053857">International University Of Health &amp; Welfare</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5579673">WO-2010046517</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="7149">Beta-galactosidase inhibitor</Action><Company id="1053857">International University Of Health &amp; Welfare</Company><Country id="ES">Spain</Country><Drug></Drug><ParentCompany id="1053857">International University Of Health &amp; Welfare</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA5579673">WO-2010046517</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="9201">Beta-glycosidase stimulator</Action><Company id="25013">Universidad de Sevilla</Company><Country id="ES">Spain</Country><Drug></Drug><ParentCompany id="25013">Universidad de Sevilla</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA5579673">WO-2010046517</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="9201">Beta-glycosidase stimulator</Action><Company id="25013">Universidad de Sevilla</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="25013">Universidad de Sevilla</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5579673">WO-2010046517</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="7149">Beta-galactosidase inhibitor</Action><Company id="25013">Universidad de Sevilla</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="25013">Universidad de Sevilla</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5579673">WO-2010046517</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="186">Beta-glucosidase inhibitor</Action><Company id="25013">Universidad de Sevilla</Company><Country id="ES">Spain</Country><Drug></Drug><ParentCompany id="25013">Universidad de Sevilla</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA5579673">WO-2010046517</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="186">Beta-glucosidase inhibitor</Action><Company id="25013">Universidad de Sevilla</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="25013">Universidad de Sevilla</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5579673">WO-2010046517</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="7149">Beta-galactosidase inhibitor</Action><Company id="25013">Universidad de Sevilla</Company><Country id="ES">Spain</Country><Drug></Drug><ParentCompany id="25013">Universidad de Sevilla</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA5579673">WO-2010046517</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="9201">Beta-glycosidase stimulator</Action><Company id="25971">Tottori University</Company><Country id="ES">Spain</Country><Drug></Drug><ParentCompany id="25971">Tottori University</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA5579673">WO-2010046517</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="9201">Beta-glycosidase stimulator</Action><Company id="25971">Tottori University</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="25971">Tottori University</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5579673">WO-2010046517</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="7149">Beta-galactosidase inhibitor</Action><Company id="25971">Tottori University</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="25971">Tottori University</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5579673">WO-2010046517</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="186">Beta-glucosidase inhibitor</Action><Company id="25971">Tottori University</Company><Country id="ES">Spain</Country><Drug></Drug><ParentCompany id="25971">Tottori University</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA5579673">WO-2010046517</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="186">Beta-glucosidase inhibitor</Action><Company id="25971">Tottori University</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="25971">Tottori University</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5579673">WO-2010046517</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="7149">Beta-galactosidase inhibitor</Action><Company id="25971">Tottori University</Company><Country id="ES">Spain</Country><Drug></Drug><ParentCompany id="25971">Tottori University</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA5579673">WO-2010046517</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="9201">Beta-glycosidase stimulator</Action><Company id="21336">Consejo Superior De Investigaciones Cientificas</Company><Country id="ES">Spain</Country><Drug></Drug><ParentCompany id="21336">Consejo Superior De Investigaciones Cientificas</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA5579673">WO-2010046517</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="9201">Beta-glycosidase stimulator</Action><Company id="21336">Consejo Superior De Investigaciones Cientificas</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="21336">Consejo Superior De Investigaciones Cientificas</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5579673">WO-2010046517</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="7149">Beta-galactosidase inhibitor</Action><Company id="21336">Consejo Superior De Investigaciones Cientificas</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="21336">Consejo Superior De Investigaciones Cientificas</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5579673">WO-2010046517</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="186">Beta-glucosidase inhibitor</Action><Company id="21336">Consejo Superior De Investigaciones Cientificas</Company><Country id="ES">Spain</Country><Drug></Drug><ParentCompany id="21336">Consejo Superior De Investigaciones Cientificas</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA5579673">WO-2010046517</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="186">Beta-glucosidase inhibitor</Action><Company id="21336">Consejo Superior De Investigaciones Cientificas</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="21336">Consejo Superior De Investigaciones Cientificas</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5579673">WO-2010046517</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="7149">Beta-galactosidase inhibitor</Action><Company id="21336">Consejo Superior De Investigaciones Cientificas</Company><Country id="ES">Spain</Country><Drug></Drug><ParentCompany id="21336">Consejo Superior De Investigaciones Cientificas</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA5579673">WO-2010046517</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="8578">Alpha-glucosidase 1 stimulator</Action><Company id="1054868">Bionaturis</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="1054868">Bionaturis</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5717158">WO-2010103137</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="8578">Alpha-glucosidase 1 stimulator</Action><Company id="1054868">Bionaturis</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="1054868">Bionaturis</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5717158">WO-2010103137</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="7170">Beta-N-acetylhexosaminidase stimulator</Action><Company id="1054868">Bionaturis</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="1054868">Bionaturis</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5717158">WO-2010103137</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="7170">Beta-N-acetylhexosaminidase stimulator</Action><Company id="1054868">Bionaturis</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="1054868">Bionaturis</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5717158">WO-2010103137</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="7150">Beta-galactosidase stimulator</Action><Company id="1054868">Bionaturis</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="1054868">Bionaturis</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5717158">WO-2010103137</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="7150">Beta-galactosidase stimulator</Action><Company id="1054868">Bionaturis</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="1054868">Bionaturis</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5717158">WO-2010103137</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="60172">N-acetylgalactosamine 6 sulfatase stimulator</Action><Company id="1054868">Bionaturis</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="1054868">Bionaturis</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5717158">WO-2010103137</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="60172">N-acetylgalactosamine 6 sulfatase stimulator</Action><Company id="1054868">Bionaturis</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="1054868">Bionaturis</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5717158">WO-2010103137</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="51969">Sphingomyelin phosphodiesterase stimulator</Action><Company id="1054868">Bionaturis</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="1054868">Bionaturis</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5717158">WO-2010103137</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="51969">Sphingomyelin phosphodiesterase stimulator</Action><Company id="1054868">Bionaturis</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="1054868">Bionaturis</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5717158">WO-2010103137</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="36308">Galactocerebrosidase stimulator</Action><Company id="1054868">Bionaturis</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="1054868">Bionaturis</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5717158">WO-2010103137</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="36308">Galactocerebrosidase stimulator</Action><Company id="1054868">Bionaturis</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="1054868">Bionaturis</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5717158">WO-2010103137</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="18441">Alpha-L-iduronidase stimulator</Action><Company id="1054868">Bionaturis</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="1054868">Bionaturis</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5717158">WO-2010103137</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="16836">Acid ceramidase stimulator</Action><Company id="1054868">Bionaturis</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="1054868">Bionaturis</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5717158">WO-2010103137</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="16836">Acid ceramidase stimulator</Action><Company id="1054868">Bionaturis</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="1054868">Bionaturis</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5717158">WO-2010103137</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="18441">Alpha-L-iduronidase stimulator</Action><Company id="1054868">Bionaturis</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="1054868">Bionaturis</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA5717158">WO-2010103137</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="676">Beta-N-acetylhexosaminidase inhibitor</Action><Company id="16994">Hospital for Sick Children</Company><Country id="US">US</Country><Drug></Drug><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA6538814">US-20110195985</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="676">Beta-N-acetylhexosaminidase inhibitor</Action><Company id="16994">Hospital for Sick Children</Company><Country id="US">US</Country><Drug></Drug><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA6538814">US-20110195985</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="4154">Diagnostic agent</Action><Company id="1006569">Agency For Science Technology &amp; Research</Company><Country id="US">US</Country><Drug></Drug><ParentCompany id="1006569">Agency For Science Technology &amp; Research</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA8229147">US-20150192589</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="4154">Diagnostic agent</Action><Company id="1006569">Agency For Science Technology &amp; Research</Company><Country id="SG">Singapore</Country><Drug></Drug><ParentCompany id="1006569">Agency For Science Technology &amp; Research</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA8229147">US-20150192589</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="836">Androgen receptor modulator</Action><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><Drug id="89982">GSK-2881078</Drug><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Product (derivative)</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA8244691">WO-2015110958</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="836">Androgen receptor modulator</Action><Company id="28355">GlaxoSmithKline plc</Company><Country id="WO">World</Country><Drug id="89982">GSK-2881078</Drug><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Product (derivative)</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA8244691">WO-2015110958</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="16841">C-type natriuretic peptide ligand</Action><Company id="1007879">Ascendis Pharma A/S</Company><Country id="WO">World</Country><Drug></Drug><ParentCompany id="1007879">Ascendis Pharma A/S</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA8748861">WO-2016110577</Patent></Row><Row><Indication id="1880">Morquio disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="16841">C-type natriuretic peptide ligand</Action><Company id="1007879">Ascendis Pharma A/S</Company><Country id="EP">European Patent</Country><Drug></Drug><ParentCompany id="1007879">Ascendis Pharma A/S</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="57">Cardiovascular disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship></DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA8748861">WO-2016110577</Patent></Row></ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2>